Sunday, February 5, 2023 | Back issues
Courthouse News Service Courthouse News Service

Allergan

Shareholders say in a federal class action that Allergan's stock dropped 41 percent in 15 months upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

NEWARK, N.J. – Allergan shareholders say in a federal class action that drugmaker’s stock dropped 41 percent, from $319.47 in 2015 to $188.82 last month, upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...